For the year ending 2025-12-31, STRO made $102,484K in revenue. -$191,086K in net income. Net profit margin of -186.45%.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Revenue | 102,484 | |||
| Research and development | 166,417 | |||
| General and administrative | 41,019 | |||
| Restructuring and related costs | 53,415 | |||
| Total operating expenses | 260,851 | |||
| Loss from operations | -158,367 | |||
| Interest income | 9,251 | |||
| Non-cash interest expense related to the sale of future royalties | 38,208 | |||
| Interest and other income (expense), net | -3,855 | |||
| Loss before provision for income taxes | -191,179 | |||
| Provision for income taxes | -93 | |||
| Net loss | -191,086 | |||
| Basic EPS | -22.49 | |||
| Diluted EPS | -22.49 | |||
| Basic Average Shares | 8,497,798 | |||
| Diluted Average Shares | 8,497,798 | |||
SUTRO BIOPHARMA, INC. (STRO)
SUTRO BIOPHARMA, INC. (STRO)